Senti Biosciences Inc

For the period ended Mar 31, 2025. Filed May 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 6, 2025

SNTI$0.14-11.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity

(In thousands, except share data)

Redeemable Convertible Preferred Stock · Common Stock · Additional Paid-in Capital · Accumulated Deficit · Total Stockholders’ Equity
Shares · Amount · Shares · Amount
Balance at December 31, 2023	—	$—	4,569,900	$1	$311,256	$(244,344)	$66,913
Vesting of early exercise of common stock options	—	—	1,266	—	34	—	34
Stock-based compensation	—	—	—	—	1,258	—	1,258
Net loss	—	—	—	—	—	(12,111)	(12,111)
Balances at March 31, 2024	—	$—	4,571,166	$1	$312,548	$(256,455)	$56,094
Balances at December 31, 2024	21,157	$25,106	4,829,035	$1	$322,782	$(297,134)	$25,649
Conversion of Series A redeemable convertible preferred stock to common stock	(21,157)	(25,106)	21,157,000	2	25,104	—	25,106
Issuance of common stock for vesting of restricted stock units	—	—	17,909	—	—	—	—
Vesting of early exercise of common stock options	—	—	422	—	12	—	12
Stock-based compensation	—	—	—	—	1,204	—	1,204
Net loss	—	—	—	—	—	(14,112)	(14,112)
Balance at March 31, 2025	—	$—	26,004,366	$3	$349,102	$(311,246)	$37,859

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.